These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 21574145)
1. [Role of neuroendocrine cells in prostate cancer progression]. Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F Urologia; 2011; 78(2):126-31. PubMed ID: 21574145 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. Alberti C G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206 [TBL] [Abstract][Full Text] [Related]
3. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype]. Bonkhoff H; Fixemer T Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555 [TBL] [Abstract][Full Text] [Related]
5. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
6. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361 [TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430 [TBL] [Abstract][Full Text] [Related]
9. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate. Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867 [TBL] [Abstract][Full Text] [Related]
10. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237 [TBL] [Abstract][Full Text] [Related]
11. Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohistochemical study. Sommerfeld HJ; Partin AW; Pannek J Int Urol Nephrol; 2002; 34(3):357-60. PubMed ID: 12899227 [TBL] [Abstract][Full Text] [Related]
12. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. Mosca A; Berruti A; Russo L; Torta M; Dogliotti L J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329 [TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662 [TBL] [Abstract][Full Text] [Related]
15. Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II. Portela-Gomes GM; Grimelius L; Stridsberg M Regul Pept; 2010 Nov; 165(1):30-5. PubMed ID: 20550951 [TBL] [Abstract][Full Text] [Related]
16. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353 [TBL] [Abstract][Full Text] [Related]
18. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798 [TBL] [Abstract][Full Text] [Related]
19. [Relevance of the neuroendocrine differentiation in prostatic carcinoma]. Sauer CG; Trojan L; Grobholz R Pathologe; 2005 Nov; 26(6):444-52. PubMed ID: 16133158 [TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. di Sant'Agnese PA Cancer; 1992 Jul; 70(1 Suppl):254-68. PubMed ID: 1350941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]